Skip to main content
Skip to footer
Home
News Channels
All News
Reports
Press Room
Contact Us
About Us
All Categories
Antibodies
DNA RNA and Cells
More News
Proteins and Peptides
Small Molecules
Vaccines
Any Word
All Words
Exact Phrase
Reports
Sep 2023
CCR8-Targeted Antibody Immunotherapy Pipeline Review
300,00€
Aug 2023
Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective
2.150,00€
Aug 2023
CD40 Agonists & CD40/L Antagonists Pipeline Review
300,00€
Aug 2023
Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review
300,00€
Aug 2023
Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review
300,00€
Aug 2023
IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review
300,00€
Jul 2023
Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review
300,00€
Jul 2023
Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists
400,00€
Jul 2023
Adalimumab (Humira) Biosimilars Pipeline Review
400,00€
Jun 2023
Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review
300,00€
Jun 2023
Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review
300,00€
Jun 2023
Ranibizumab (Lucentis) Biosimilars Pipeline Review
300,00€
Jun 2023
Aflibercept (Eylea) Biosimilars Pipeline Review
300,00€
Jun 2023
Ustekinumab (Stelara) Biosimilars Pipeline Review
300,00€
Jun 2023
TSLP Pipeline Review
300,00€
Mar 2023
2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics
120,00€
Feb 2023
Antibody Target, Technology & Pipeline Database: 1-Year Subscription
1.600,00€
Feb 2023
CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing
1.800,00€
Nov 2022
RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective
2.350,00€
Jul 2022
Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
2.550,00€
1.800,00€
Jul 2022
GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
600,00€
Jun 2022
ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
1.050,00€
May 2022
Cadherin 17: A target opportunity to develop effector-enhanced drug modalities
400,00€
May 2022
Claudin 6: A target opportunity to develop effector-enhanced drug modalities
500,00€
Mar 2022
Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing
2.450,00€
←
1
2
3
→
Any Word
All Words
Exact Phrase
Report categories
Antibody & Protein Sales
Antibody Technologies
Biosimilar Antibodies & Proteins
CAR T-Cells
Drug the Undruggable Technologies
Immuno-Oncology
mRNA Vaccines & Therapeutics
NK Cells & CAR Macrophages
Pipeline Database
RNA-Targeted Therapeutics
Target Pipelines
TCR T-Cells and Antibodies
Therapeutic Antibodies
Therapeutic Proteins & Peptides
